Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785798 · ClinicalTrials.gov registry record · Phase 1
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00785798 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT00785798, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
Interventions
- DRUG Vorinostat
- DRUG Pegylated Liposomal Doxorubicin (PLD), Doxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785798
The ClinicalTrials.gov registry entry for NCT00785798 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT00785798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785798 about?
NCT00785798 is a clinical study titled "Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas". The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
What is the current status of trial NCT00785798?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00785798?
The interventions under investigation include: Vorinostat (DRUG), Pegylated Liposomal Doxorubicin (PLD), Doxil (DRUG).
Who is sponsoring clinical trial NCT00785798?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.